Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cullinan Oncology, Inc. CGEM
$9.55
-$0.07 (-0.73%)
На 18:03, 12 мая 2023
+98.95%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
382714869.00000000
-
week52high
15.89
-
week52low
7.30
-
Revenue
0
-
P/E TTM
4
-
Beta
0.09540800
-
EPS
2.39000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 13 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 мар 2022 г. |
| Morgan Stanley | Overweight | Overweight | 07 июн 2021 г. |
| SVB Leerink | Outperform | Outperform | 04 июн 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 04 июн 2021 г. |
| BTIG | Buy | 21 ноя 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BVF PARTNERS L P/IL | A | 30000 | 30000 | 19 янв 2023 г. |
| BVF PARTNERS L P/IL | A | 260000 | 260000 | 19 янв 2023 г. |
| BVF PARTNERS L P/IL | A | 350000 | 350000 | 19 янв 2023 г. |
| BVF PARTNERS L P/IL | D | 64161 | 300000 | 19 янв 2023 г. |
| BVF PARTNERS L P/IL | D | 392808 | 2600000 | 19 янв 2023 г. |
| BVF PARTNERS L P/IL | D | 558854 | 3500000 | 19 янв 2023 г. |
| Trigilio Jeffrey | A | 41402 | 201 | 30 дек 2022 г. |
| Michaelson Jennifer | D | 200593 | 4000 | 25 ноя 2022 г. |
| Michaelson Jennifer | D | 53031 | 4000 | 25 ноя 2022 г. |
| Michaelson Jennifer | A | 57031 | 4000 | 25 ноя 2022 г. |
Новостная лента
Cullinan Oncology to Participate in Upcoming Investor Conferences
GlobeNewsWire
01 ноя 2022 г. в 07:00
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that its management team will participate in the following investor conferences.
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Seeking Alpha
22 сент 2022 г. в 06:16
Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after.
Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Seeking Alpha
14 сент 2022 г. в 14:45
Cullinan Oncology's total cash and short-term investment is $611 million, up 94% from the previous quarter. The company's portfolio consists of eight product candidates that can significantly improve the quality of life of patients suffering from various types of cancer.
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
GlobeNewsWire
07 сент 2022 г. в 08:00
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Company management will participate in the following investor conferences:
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
GlobeNewsWire
19 мая 2022 г. в 08:00
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 in Miami, FL and virtually.